Merck makes a new move in Astra battle
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The month ahead: May’s upcoming events
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
AACR 2026 – Matisse paints a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
Gilead edges further away from Arcus
The disclosure comes as another of Arcus's TIGIT trials flops.
Astra goes subcutaneous in its Merck race
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
The month ahead: April’s upcoming events
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Pfizer bags a hormone-sensitive win
Talapro-3 could help move Talzenna into earlier prostate cancer.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
